M&A Deal Summary |
|
|---|---|
| Date | 2024-04-10 |
| Target | SaveWay |
| Sector | Life Science |
| Buyer(s) | Myonexus Therapeutics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2017 |
| Sector | Life Science |
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb girdle muscular dystrophies (LGMDs) based on research at Nationwide Children’s Hospital, a provider in neuromuscular gene therapy discovery and translational research. Myonexus Therapeutics was founded in 2017 and is based in New Albany, Ohio.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Delaware M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-15 |
Creapharm’s Clinical & Commercial Packaging and Bioservices Business
Reims, France Creapharm’s Clinical & Commercial Packaging and Bioservices Business provides clinical packaging and distribution to commercial packaging and advanced therapy medicinal products (ATMPs) supply chain management. |
Buy | - |